✦ LIBER ✦

Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin

✍ Scribed by M. G. Antonini; S. Babudieri; I. Maida; C. Baiguera; B. Zanini; L. Fenu; G. Dettori; D. Manno; M. S. Mura; G. Carosi; M. Puoti

Book ID: 107705626
Publisher: Springer-Verlag
Year: 2008
Tongue: English
Weight: 271 KB
Volume: 36
Category: Article
ISSN: 0300-8126
DOI: 10.1007/s15010-007-7132-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Cost-effectiveness of interferon alfa 2b

Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C

✍ W. Ray Kim; John J. Poterucha 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment. This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to th

Efficacy and safety of pegylated IFN alf

Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C

✍ Ajit Sood; Praveen Sobti; Vandana Midha; Dinesh Singla; Amarjeet Kaur; Sandeep K 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 112 KB

Association of host pharmacodynamic effe

Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C

✍ Raymond T. Chung; Fred F. Poordad; Tarek Hassanein; Xiaolei Zhou; Ellen Lentz; A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 773 KB

Patients receiving therapy for chronic hepatitis C virus (HCV) infection frequently experience cytopenias and weight loss. We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic par

Interferon alfa-2b in combination with r

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics

✍ Regino P. González-Peralta; Deirdre A. Kelly; Barbara Haber; Jean Molleston; Kar 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 3 views

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh

Is an “à la carte” combination interfero

Is an “à la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?

✍ Thierry Poynard; John McHutchison; Zachary Goodman; Mei-Hsiu Ling; Janice Albrec 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views

Randomized trials have shown the enhancement of efficacy with interferon alfa-2b and ribavirin (IFN-R) in comparison with interferon monotherapy (IFN) as first line treatment of chronic hepatitis C. Further definition of response based on disease, patient, and treatment characteristics is needed to